Login / Signup

The locoregional adiponectin and its synergistic antitumor effect with HIF-1α blockade in TSCC.

Xiao-Hong GuoMing-Yu WuGang ZhaoFeng-Hua WuYun-Dan XuMing-Zhu YinLei Xiang
Published in: Oral diseases (2021)
Adiponectin (APN) is a kind of endogenous anti-tumor adipocytokine, which exerts its function by binding to its receptors (AdipoR1 and AdipoR2). However, hyperadiponectinemia is found in some pathophysiological processes without significant protective effect, which indicates the existence of APN resistance. Here, we aimed to investigate the locoregional expression of APN in tongue squamous cell carcinoma (TSCC) tissues, and to explore the potential regulatory mechanism of APN resistance under hypoxia. Consequently, we found that the protein expression of APN and AdipoR1, but not AdipoR2, was upregulated in the early stage of TSCC and after hypoxic treatment ex vivo and in vitro. Knockdown of HIF-1α decreased the level of APN and AdipoR1, and simultaneously, HIF-1α was identified as transcriptor of the APN. Intriguingly, a regenerative feedback of HIF-1α was unexpectedly detected after application of recombinant globular APN (gAPN), which most likely contributed to the APN resistance. Furthermore, HIF-1α blockade combined with gAPN has a prominent synergistic antitumor effect, which suggested an effective amelioration in APN resistance. In all, our study revealed the possible mechanism of APN resistance under hypoxia and provides a promising strategy of bi-target treatment with APN and HIF-1α for TSCC therapy.
Keyphrases
  • endothelial cells
  • early stage
  • squamous cell carcinoma
  • stem cells
  • metabolic syndrome
  • type diabetes
  • poor prognosis
  • cancer therapy
  • cell therapy
  • radiation therapy
  • bone marrow
  • locally advanced
  • neoadjuvant chemotherapy